Novel insights into lncRNAs as key regulators of post-translational modifications in cancer: mechanisms and therapeutic potential.

IF 4.8 2区医学 Q2 CELL BIOLOGY

Cellular Oncology Pub Date : 2025-07-02 DOI:10.1007/s13402-025-01086-1

Yaqian Han, Shizhen Li, Linda Oyang, Shiwen Cui, Wenlong Zhang, Wenjuan Yang, Mingjing Peng, Shiming Tan, Longzheng Xia, Jinguan Lin, Xuemeng Xu, Nayiyuan Wu, Xianjie Jiang, Qiu Peng, Yanyan Tang, Xia Luo, Qianjin Liao, Yujuan Zhou

{"title":"Novel insights into lncRNAs as key regulators of post-translational modifications in cancer: mechanisms and therapeutic potential.","authors":"Yaqian Han, Shizhen Li, Linda Oyang, Shiwen Cui, Wenlong Zhang, Wenjuan Yang, Mingjing Peng, Shiming Tan, Longzheng Xia, Jinguan Lin, Xuemeng Xu, Nayiyuan Wu, Xianjie Jiang, Qiu Peng, Yanyan Tang, Xia Luo, Qianjin Liao, Yujuan Zhou","doi":"10.1007/s13402-025-01086-1","DOIUrl":null,"url":null,"abstract":"<p><p>Abnormal post-translational modifications (PTMs) play a crucial role in tumor initiation and progression. However, the mechanisms by which lncRNAs, as emerging epigenetic regulators, mediate PTMs remain largely unexplored. This review provides a comprehensive summary of the latest research on the interplay between lncRNA-mediated PTMs and tumorigenesis. We delve into the molecular mechanisms underlying these interactions, focusing on how lncRNAs regulate PTMs to influence tumor progression. We place particular emphasis on the lncRNA-mediated PTMs as a driver of therapeutic resistance, shedding light on its potential as a novel target for cancer intervention. Furthermore, we highlight the therapeutic potential of targeting lncRNA-PTM networks, emphasizing novel RNA-based strategies and their clinical relevance in cancer treatment. We believe that an in-depth understanding of lncRNA-mediated PTMs could uncover novel therapeutic targets, paving the way for innovative approaches in cancer diagnosis and treatment.</p>","PeriodicalId":49223,"journal":{"name":"Cellular Oncology","volume":" ","pages":""},"PeriodicalIF":4.8000,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cellular Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s13402-025-01086-1","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CELL BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Abnormal post-translational modifications (PTMs) play a crucial role in tumor initiation and progression. However, the mechanisms by which lncRNAs, as emerging epigenetic regulators, mediate PTMs remain largely unexplored. This review provides a comprehensive summary of the latest research on the interplay between lncRNA-mediated PTMs and tumorigenesis. We delve into the molecular mechanisms underlying these interactions, focusing on how lncRNAs regulate PTMs to influence tumor progression. We place particular emphasis on the lncRNA-mediated PTMs as a driver of therapeutic resistance, shedding light on its potential as a novel target for cancer intervention. Furthermore, we highlight the therapeutic potential of targeting lncRNA-PTM networks, emphasizing novel RNA-based strategies and their clinical relevance in cancer treatment. We believe that an in-depth understanding of lncRNA-mediated PTMs could uncover novel therapeutic targets, paving the way for innovative approaches in cancer diagnosis and treatment.

查看原文本刊更多论文

lncrna作为癌症翻译后修饰关键调控因子的新见解：机制和治疗潜力。

异常翻译后修饰（PTMs）在肿瘤的发生和发展中起着至关重要的作用。然而，lncrna作为新兴的表观遗传调节剂，介导ptm的机制在很大程度上仍未被探索。本文综述了lncrna介导的ptm与肿瘤发生相互作用的最新研究进展。我们深入研究了这些相互作用的分子机制，重点关注lncrna如何调节PTMs以影响肿瘤进展。我们特别强调lncrna介导的ptm作为治疗耐药的驱动因素，揭示了其作为癌症干预新靶点的潜力。此外，我们强调靶向lncRNA-PTM网络的治疗潜力，强调新的基于rna的策略及其在癌症治疗中的临床意义。我们相信，深入了解lncrna介导的PTMs可以发现新的治疗靶点，为癌症诊断和治疗的创新方法铺平道路。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cellular Oncology ONCOLOGY-CELL BIOLOGY

CiteScore

10.30

自引率

1.50%

发文量

审稿时长

12 months

期刊介绍： The Official Journal of the International Society for Cellular Oncology Focuses on translational research Addresses the conversion of cell biology to clinical applications Cellular Oncology publishes scientific contributions from various biomedical and clinical disciplines involved in basic and translational cancer research on the cell and tissue level, technical and bioinformatics developments in this area, and clinical applications. This includes a variety of fields like genome technology, micro-arrays and other high-throughput techniques, genomic instability, SNP, DNA methylation, signaling pathways, DNA organization, (sub)microscopic imaging, proteomics, bioinformatics, functional effects of genomics, drug design and development, molecular diagnostics and targeted cancer therapies, genotype-phenotype interactions. A major goal is to translate the latest developments in these fields from the research laboratory into routine patient management. To this end Cellular Oncology forms a platform of scientific information exchange between molecular biologists and geneticists, technical developers, pathologists, (medical) oncologists and other clinicians involved in the management of cancer patients. In vitro studies are preferentially supported by validations in tumor tissue with clinicopathological associations.